TABLE 1.
Characteristics of pulmonary Mycobacterium abscessus complex studies identified through systematic review
| Reference | Enrollment period | Study location (referral) | Study designa | No. of patients | Age, yr (range) | Male/female ratio | Outcome(s) examinedb | No. (%) who died on therapyc,f |
|---|---|---|---|---|---|---|---|---|
| Macrolide-free regimens | ||||||||
| Griffith et al. (21) | 1976–1991 | Texas (southern USA) | RetroCS | 120 | 54 ± 19.6 | 42:78 | SCC, relapse, death | 20 (17) |
| Macrolide-containing regimens | ||||||||
| van Ingen et al. (32) | 1999–2005 | Netherlands | RetroCS | 30 | 53 (1–89) | 19:11 | SCC, death | 4 (8) |
| Jeon et al. (14) | 2000–2007 | Seoul, South Korea | RetroCS | 188 | 55 (43–67) | 48:140 | SCC, relapse, death (RSS) | 2 (1)d |
| Jarand et al. (23) | 2001–2004 | Colorado, USA (36 states) | RetroCS | 107 | 60.2 (20–85) | 18:89 | SCC, relapse, death | 17 (16) |
| Lyu et al. (26) | 2003–2008 | Seoul, South Korea | RetroCS | 112 | 53.2 (22–77) | 10:31 | SCC, relapse, death | 0 |
| Koh et al. (15) | 2004–2008 | Seoul, South Korea | RetroCS | 145 | 57.6 ± 13.0 | 37:108 | SCC, relapse (RSS) | 0 |
| Harada et al. (22) | 1990–2010 | Japan (12 centers) | RetroCS | 102 | 68 (27–94) | 39:58e | SCC, relapse (radiographic) | 0 |
| Tung et al. (31) | 2006–2012 | Kaohsiung, Taiwan | RetroCS | 106 | 64.56 ± 14.11 | 44:62 | SCC, relapse, death (radiographic) | 15 (14) |
| Griffith et al. (7) | 2000–2012 | Texas, USA | RetroCS | 21 | 75.5 ± 8.5 | 2:19 | SCC, relapse | 0 |
| Namkoong et al. (27) | 2004–2013 | Tokyo, Japan | RetroCS | 92 | 63.6 ± 8.5 | 2:11 | SCC (radiographic) | NA |
| Koh et al. (25) | 2007–2012 | Seoul, South Korea | ProspCS | 71 | 57 (50–64) | 10:61 | SCC (RSS) | NA |
| Czaja et al. (20) | 2009–2012 | Colorado, USA (southern states) | ProspCS | 53 | 65 ± 11 | 7:40 | SCC (RSS) | NA |
| Koh et al. (24) | 2002–2012 | Seoul, South Korea | ProspCS | 67 | 57 (48–64) | 15:52 | SCC (RSS) | NA |
| Park et al. (30) | 2006–2015 | Seoul, South Korea | RetroCS | 113 | 64 (52–71) | 39:71 | SCC (RSS) | NA |
| Macrolide-containing plus Investigational drugs in refractory diseaseg | ||||||||
| Olivier et al. (29) | 2003–2010 | Maryland, USA | RetroCS of inhaled amikacin | 23 | 56 ± 16 | 4:16 | SCC | NA |
| Wallace et al. (33) | 2002–2006 | Texas, USA | ProspCS of tigecycline | 36 | 35.2 ± 22.2 | 7:29 | SCC | NA |
| Yang et al. (34) | 2013–2015 | Seoul, South Korea | RetroCS of clofazimine | 42 | 60 (53–69) | 9:33 | SCC (RSS) | NA |
| Olivier et al. (28) | 2012–2015 | North America (Canada and USA) | RCT of liposomal amikacin (NCT01315236) | 90 | 58.5 ± 15.83 | 11:78 | Semiquantitative mycobacterial growth scale, SCC, 6-min walk, adverse events | 2 (2.2) |
| Choi et al. (19) | 2005–2015 | Seoul, South Korea | RetroCS | 15 | 57 (48–67) | 5:10 | SCC, death | 5 (33) |
a
RCT, randomized control trial; ProspCS, prospective cohort study; RetroCS, retrospective cohort study.
b
SCC, sputum culture conversion; RSS, radiographic, symptomatic response.
c
NA, data not available.
d
Studies that only reported deaths due to pulmonary Mycobacterium abscessus complex disease in treated patients.
e
Some data of patients with Mycobacterium abscessus subspecies bolletii are missing.
f
Data analyzed or available in text or tables only.
g
Refractory means failing initial therapy.